From August 25 to 27, 2026, CPHI Korea 2026 was successfully held at COEX Convention & Exhibition Center in Seoul, South Korea.
ECHEMI, together with its digital platform ECHEMI.COM and ECHEMI Pharma business team, engaged in in-depth exchanges with pharmaceutical companies, raw material suppliers, and professional procurement professionals from over 70 countries and regions around the world.
As one of the important pharmaceutical industry professional exhibitions in South Korea and the Asia-Pacific region, CPHI Korea covers multiple sectors including APIs, pharmaceutical excipients, finished dosage forms, biotechnology, CDMO, pharmaceutical packaging equipment, laboratory analytical instruments, and nutritional health ingredients. This year’s exhibition spanned Hall C, Hall E, and The Platz area, with a total exhibition space of 13,000 square meters—an increase of approximately 14% over the previous edition—attracting participants from across the global pharmaceutical supply chain.
The conference agenda at CPHI Korea 2026 expanded from four concurrent tracks last year to six tracks, featuring topics such as AI-driven drug discovery, next-generation biologics modalities, regenerative medicine, health functional foods, global regulatory affairs, and export strategies.
In the biopharmaceutical sector, special sessions highlighted South Korea’s emerging “K-platform” technologies, including antibody-drug conjugates (ADCs), targeted protein degradation (TPD), and recombinant protein therapeutics (RPT).
In addition, multiple specialized events were held concurrently, including the Bio-Health Policy Forum hosted by the Korea Drug Research Association (KDRA), a microneedle technology seminar, and an AI drug discovery symposium. Major government and industry bodies such as the Ministry of Food and Drug Safety (MFDS), the Korea Foundation for Regenerative Medicine (KFRM), the Korea Institute of Toxicology (KIT), and the Korea Health Functional Food Association (KHFF) also actively participated in the exhibition.
As a chemical supply chain service enterprise headquartered in Hong Kong, ECHEMI’s business covers chemical raw material supply, digital trading, market research and analysis, distribution, logistics, and other segments, providing efficient product trade and market matchmaking support to upstream and downstream enterprises in the global chemical industry chain.
During the exhibition, ECHEMI fully demonstrated its digital platform services and pharmaceutical raw material supply capabilities, engaging in discussions with overseas pharmaceutical companies and raw material purchasers on product demand and supply cooperation for APIs, pharmaceutical intermediates, and related products.
The ECHEMI.COM team focused on showcasing the application of its digital B2B platform in the pharmaceutical and chemical sectors. The platform connects global suppliers and purchasing enterprises, offering suppliers product display, overseas market expansion, and buyer access channels, while helping procurement companies access product information and supply resources. Currently, ECHEMI.COM covers fine chemicals, pharmaceuticals, food additives, and other fields, with over 1 million SKUs, serving more than 130,000 buyers and 24,000 suppliers worldwide.
Meanwhile, the ECHEMI Pharma team presented its supply capabilities for APIs, pharmaceutical intermediates, food additives, and other products, introducing the company’s pharmaceutical raw material supply capacity and supply chain service system to overseas clients.
Throughout the exhibition, the team held in-depth discussions with pharmaceutical companies and raw material purchasers on product requirements, supply cooperation, and long-term market partnership opportunities.
By participating in CPHI Korea 2026, ECHEMI further strengthened its engagement with the global pharmaceutical industry chain, expanded international cooperation opportunities in the pharmaceutical raw material sector, and reaffirmed its commitment to providing more professional market services to customers worldwide.
